| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Nant Health (NH) | Jefferies/ Cowen and Company | $92.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Mammoth Energy Partners LP (TUSK) | Credit Suisse | $100.00 | n.a. | |||
| n.a. (not available) | ||||||
| New Terms | ||||||
| Acacia Communications (ACIA) | Goldman Sachs/ BofA Merrill Lynch/ Deutsche Bank Securities | 4.50 | $21.00 | $23.00 | $99.00 | 2-Stars |
| PhaseRx (PZRX) | Laidlaw & Company (UK) Ltd. | 3.70 | $5.00 | $7.00 | $22.20 | n.a. |
| SiteOne Landscape Supply (SITE) | Deutsche Bank Securities/ Goldman Sachs/ UBS Investment Bank | 10.00 | $20.00 | $22.00 | $210.00 | 1-Star |
| Viamet Pharmaceuticals (VMET) | Morgan Stanley/ Goldman Sachs | 5.70 | $14.00 | $16.00 | $85.50 | 1-Star |
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of May 2, 2016 | Manager(s) | Offered | Raised | Price | 5/6/16 | Change |
| Intellia Therapeutics (NTLA) | Credit Suisse/ Jefferies/ Leerink Partners | 6.00 | $108.00 | $18.00 | $22.10 | 22.78% |
| Spring Bank Pharmaceuticals (SBPH) | Dawson James Securities | 0.92 | $11.04 | $12.00 | $11.10 | -7.50% |
